Chinese Orals at ESMO 2026: Dual TKI Overcomes MET-Amplified Resistance; CS2009 and Ivonescimab Data
Start here
Three Chinese-led oral presentations at ESMO 2026 delivered updated results across MET-amplification resistance, non-small cell lung cancer, and thymic carcinoma. The headline result came from a randomized phase 3 trial (NCT06110663), where a dual-TKI regimen significantly improved progression-free survival in MET-amplified resistance: 314 patients were randomized, and IRC-assessed median PFS was 6.2 versus 4.4 months, with HR 0.601 and P<0.001. Separately, CS2009 showed preliminary activity in the evaluable first-line PD-L1 TPS≥50% population, with an ORR of 81.3% and a disease control rate of 100%. Full details of the ivonescimab thymic carcinoma data and longer-term follow-up across these studies are still to come.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickESMO 2026 Chinese Orals: Dual TKI Improves MET-Amplified Resistance, CS2009 and Ivonescimab Report NSCLC and Thymic Carcinoma Data
Three Chinese-led oral presentations at ESMO 2026 updated data on MET-amplification resistance, NSCLC, and thymic carcinoma. A dual-TKI regimen significantly improved PFS in a randomized phase 3 study: NCT06110663 randomized 314 patients, with IRC-assessed mPFS of 6.2 vs 4.4 months, HR 0.601, P<0.001. CS2009 showed a preliminary ORR/DCR of 81.3%/100% in the evaluable first-line PD-L1 TPS≥50% population.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 16:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.